Is testosterone therapy contraindicated in a man with benign prostatic hyperplasia (BPH)?

Testosterone is NOT contraindicated in patients with benign prostatic hyperplasia (BPH)

Testosterone therapy can be safely administered to men with BPH, as current evidence shows no worsening of lower urinary tract symptoms and may even provide benefit, though appropriate monitoring is essential.

Key Evidence from Guidelines and FDA Labeling

The FDA label for testosterone lists BPH as a precaution, not a contraindication 1. The label specifically states that "patients with benign prostatic hypertrophy may develop acute urethral obstruction" and recommends stopping the androgen if this occurs, then restarting at a lower dose if appropriate 1. Notably, the actual FDA contraindications are limited to: known hypersensitivity, male breast or prostate cancer, pregnancy, and serious cardiac/hepatic/renal disease 1.

The 2018 AUA Guideline on Testosterone Deficiency does not list BPH as a contraindication 2. Instead, it focuses monitoring recommendations on PSA screening (for men over 40) and appropriate patient selection based on prostate cancer risk, not BPH status 2.

Clinical Evidence on BPH and Testosterone

The relationship between testosterone and BPH contradicts historical assumptions:

• No worsening of symptoms: Multiple studies demonstrate that testosterone therapy does not exacerbate lower urinary tract symptoms (LUTS) 3, 4, 5
• Potential improvement: Some evidence suggests testosterone may actually improve LUTS by reducing prostatic inflammation and improving metabolic syndrome components 6, 4, 7
• Low testosterone may contribute to BPH: Recent evidence indicates that low (not high) testosterone levels and hyperestrogenism may favor prostate inflammation and BPH development 6

However, the most recent large-scale study from 2025 found that after 2.5 years of therapy, men on testosterone had a 32% higher risk of receiving a BPH diagnosis, though this did not translate to increased need for interventions 8, 9.

Practical Management Algorithm

Before initiating testosterone:

1. Establish baseline voiding symptoms using standardized questionnaire 10
2. Perform digital rectal examination 10, 2
3. Measure PSA in men over 40 2
4. Counsel that BPH is not a contraindication but requires monitoring

During therapy:

• Monitor urinary symptoms every 3-6 months in first year, then annually 10
• If acute urinary retention develops, stop testosterone temporarily and consider lower dose upon restart 1
• Continue routine PSA and prostate monitoring per standard guidelines 2

Common Pitfalls to Avoid

• Don't confuse BPH with prostate cancer: BPH is a precaution requiring monitoring; prostate cancer is the actual contraindication 1
• Don't withhold therapy based on BPH alone: The evidence does not support this practice 3, 4, 5
• Don't ignore metabolic factors: Treating hypogonadism may improve metabolic syndrome, which itself contributes to LUTS 6
• Watch for acute obstruction: While rare, men with significant BPH may develop acute urethral obstruction requiring immediate intervention 1

The historical view that testosterone worsens BPH stems from the androgen-dependence of early prostate development, but this does not translate to clinical worsening in adult men with established BPH 6, 4.